Updated November 14, 2026
Polycystic kidney disease (PKD) is the most common inherited kidney disease affecting one in 800 people. There have been several advances in our understanding of PKD since our last blog. In a previous blog, we discussed the genetics of PKD and how genetic variants translate into a disease. In this blog, we will discuss recommendations for water, salt, and caffeine intake to reduce cyst growth. You will find out if ketogenic diet or intermittent fasting is the best diet for polycystic kidney disease.
PKD at the Cellular Level
To determine the best PKD diet and lifestyle recommendations, we must understand what is happening at the cellular level. In essence, abnormalities in PC1 or PC2 proteins will activate two pathways inside the cell. First, it activates the cAMP pathway which regulates fluid transport. Second, it changes the way cells make energy from sugar (called glycolysis). When PC1 or PC2 proteins don’t work well, cyst-lining cells can become more reliant on aerobic glycolysis: using glucose through glycolysis even when oxygen is available. This resembles a metabolic shift seen in cancer cells.
This altered metabolism can support cell growth and increase dependence on glucose, providing a rationale for studying metabolic interventions in PKD.
Hydration in ADPKD
Vasopressin, also called antidiuretic hormone (ADH), helps the kidneys conserve water. In ADPKD, it also stimulates signaling that can promote cyst growth. Drinking water can suppress vasopressin release, providing a biologically plausible reason why adequate hydration may help. Animal studies support this approach, but biological plausibility and demonstrated human benefit are not the same thing.
The PREVENT-ADPKD trial followed 184 adults for three years. Prescribed water intake lowered urine concentration but did not significantly slow kidney-volume growth compared with usual intake. Only about half achieved the urine-concentration target, and the intervention did not significantly lower copeptin, a marker of vasopressin. The findings do not erase the rationale for avoiding dehydration, but we cannot promise that drinking more water will slow ADPKD. Read the trial.
For eligible adults with ADPKD and eGFR of at least 30, KDIGO suggests approximately 2–3 liters of water daily, spread throughout the day. This is not a universal prescription: advanced kidney disease, low blood sodium, fluid overload and certain medications can change what is safe. People taking tolvaptan need a separate hydration plan. KDIGO guideline.
Our water-intake calculator uses 24-hour urine volume and osmolality to support a clinical discussion. Its estimate is not a stand-alone prescription or a proven target for slowing cyst growth. More water is not always better.
Polycystic Kidney Disease and Caffeine
In the laboratory, caffeine increased cAMP accumulation in the cells. Yet, in human clinical trials, caffeine intake was not directly associated with kidney size in patients with PKD. An analysis in one clinical trial found no significant association between the consumption of caffeine from coffee and tea on the progression of ADPKD.
Ketogenic nutrition and fasting: growing human evidence
ADPKD is genetic, but its course is also influenced by cellular metabolism. Ketogenic approaches aim to change the metabolic environment through carbohydrate restriction and ketone production. They are not necessarily high-protein diets, and fasting, carbohydrate restriction and calorie restriction should not be treated as interchangeable interventions.
- KETO-ADPKD: This exploratory randomized trial assigned 66 adults to a ketogenic diet, periodic water fasting or usual diet for three months. The ketogenic group had encouraging improvements in estimated kidney function, body fat and liver volume, although kidney-volume changes did not reach statistical significance. The study was short, and longer trials are needed to determine whether these changes translate into lasting kidney protection. Read the study.
- Ren-Nu: A real-world evaluation of 103 participants combined ketogenic nutrition, education, lifestyle changes and KetoCitra. Over approximately three months, participants had a reported average 6.3% improvement in eGFR, alongside improvements in weight and symptoms. This is encouraging, but there was no separate control group, and the combined intervention cannot identify which component produced the changes. We discussed it in our February 2026 Research & News. Original study.
- Longer-term imaging: A 2026 case series described four people using differing combinations of carbohydrate restriction, fasting and ketone/citrate supplementation for six months to approximately four years. Kidney volumes stabilized or decreased relative to prior growth patterns, with preserved kidney function. These are promising observations, but four self-selected cases cannot establish causation or predict results for other patients. Read the case series.
The Ren-Nu and case-series reports disclose commercial relationships with the supplement manufacturer. Independent controlled trials will strengthen confidence in these findings.
Fasting deserves its own discussion. A 29-person, 12-month randomized pilot found no significant advantage in kidney-volume change from an eight-hour eating window compared with healthy-eating advice. It does not rule out other metabolic approaches, but cautions against assuming all forms of fasting have the same effects as a ketogenic diet. Read the trial, also covered in our April 2025 newsletter.
Ketogenic nutrition is a promising research direction, not an established cure or proven way to prevent kidney failure. Current KDIGO guidance advises against routine implementation while stronger controlled evidence is awaited. People considering it should discuss the uncertainties with their nephrologist and a renal dietitian, with attention to nutritional adequacy, medications, lipid profile and stone risk.
Putting the plan together
An integrative ADPKD plan addresses the metabolic and lifestyle environment alongside the genetic diagnosis: food quality, sodium, appropriate protein and energy intake, healthy weight, activity, sleep, stress and individualized hydration. Emerging metabolic therapies deserve serious attention without promising more than the evidence shows. They should complement, not replace, indicated medical treatment.
Stress management can support well-being, but has not been shown to shrink kidney cysts.
What We Still Need to Learn
PREVENT-ADPKD and KETO-ADPKD have now reported results, as summarized above. The evidence has moved beyond the studies that were still ongoing when this article was first published in 2021.
The key questions are whether metabolic interventions provide sustained benefits in kidney growth and function, which patients benefit most, and how to achieve long-term nutritional safety and adherence. Adequately powered trials with longer follow-up are needed to distinguish encouraging early changes from durable disease modification.





